Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring Surgery
Aesthetic Surgery Journal · 17.03.2025 · 45 (4) · 381-386
DOI: 10.1093/asj/sjae241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 12.12.2024. Verfasst von Joshua E Lewis und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Body Contouring, Postoperative Complications, Bariatric Surgery. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIH, NIH HHS.
Abstract (Originalsprache)
Background
Semaglutide is a medication for weight loss in obese patients. Recently, many plastic surgeons have recommended semaglutide following bariatric surgery to increase weight loss. However, postoperative complications such as wound dehiscence, delayed healing, and infection pose significant risks.
Objectives
In this study we aimed to examine the relationship between preoperative semaglutide and postoperative complications in nondiabetic obese patients undergoing body contouring surgery. We hypothesized that semaglutide would increase the risk of postoperative complications.
Methods
In this retrospective cohort study we utilized the TriNetX Research database. Nondiabetic patients who underwent body contouring surgery between 2021 and 2024 after bariatric procedures were included. Patients were divided into 2 cohorts: Cohort A (4215 patients), which received semaglutide for ≥6 months before surgery, and Cohort B (104,927 patients), without semaglutide. Propensity score matching was employed to create comparable cohorts based on age, gender, race, and BMI. The primary outcomes included postoperative complications within 30 days of surgery.
Results
Significant differences were found between the cohorts. Semaglutide patients had higher rates of wound dehiscence (5.19% vs 2.78%, P < .0001); delayed wound healing (2.58% vs 1.21%, P < .0001); surgical site infections (5.37% vs 2.87%, P < .0001); nausea, vomiting, and diarrhea (11.27% vs 5.34%, P < .0001); hypertrophic scar formation (5.53% vs 3.86%, P = .0011); and surgical site pain (6.05% vs 3.29%, P < .0001).
Conclusions
Preoperative semaglutide in nondiabetic patients undergoing body contouring surgery following bariatric procedures is associated with higher rates of adverse postoperative outcomes. These findings highlight the need for enhanced preoperative counseling and surgical planning to minimize risks and improve patient outcomes. Level of Evidence: 3 (Therapeutic)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Joshua E Lewis
Förderung
- NCATS NIH HHS
- NIH
- NIH HHS
- UTMB Institute for Translational Sciences
- National Center for Advancing Translational Sciences
- National Institutes of Health
Zitieren
APA
Lewis, J. E., Ghogomu, M., Hickman, S. J., Ashade, A., Hollis, R. J., Lewis, J. E., & Lee, W. C. (2025). Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring Surgery. Aesthetic Surgery Journal, 45(4), 381-386. https://doi.org/10.1093/asj/sjae241
Vancouver
Lewis JE, Ghogomu M, Hickman SJ, Ashade A, Hollis RJ, Lewis JE, et al. Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring Surgery. Aesthetic Surgery Journal. 2025;45(4):381-386. doi:10.1093/asj/sjae241
BibTeX
@article{Lewis2025,
author = {Lewis, Joshua E and Ghogomu, Mbinui and Hickman, Stanley J and Ashade, Adedamola and Hollis, Raven J and Lewis, Jimmie E and Lee, Wei-Chen},
title = {Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring Surgery},
journal = {Aesthetic Surgery Journal},
year = {2025},
volume = {45},
number = {4},
pages = {381--386},
doi = {10.1093/asj/sjae241}
}
EUVIMED